Kim, R. D., Saeed, A., Chapin, W. J., Kim, K., Iyer, R., Martin, R. C., Grothey, A., Gadde, S., Feun, L. G., Gabayan, A., Saenger, Y. M., Abdelrahim, M., Govada, N., Xie, B., Cho, M., Burgoyne, A. (2026). A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps614